GlassScriptPhysician profile
Stanley S Sugarman
NPI 1497791230
$6,789.71
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,657 · 2020: $652 · 2021: $1,665 · 2022: $1,794 · 2023: $21.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $873.88 | 2019-2022 | |
| Abbvie INC. | $809.80 | 2019-2023 | Qulipta |
| Amgen INC. | $735.11 | 2019-2022 | |
| Novo Nordisk INC | $560.60 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $430.12 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $429.79 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $397.23 | 2019-2022 | |
| Lilly USA, LLC | $380.50 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $331.35 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $282.71 | 2019-2022 | |
| Astellas Pharma US INC | $188.20 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $138.79 | 2022 | |
| Amarin Pharma, INC. | $130.91 | 2019-2021 | |
| Glaxosmithkline, LLC. | $109.25 | 2019-2022 | |
| Boston Scientific Corporation | $97.27 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $91.05 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $89.31 | 2019-2022 | |
| Gilead Sciences, INC. | $85.81 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $63.68 | 2021 | |
| Cmp Pharma, INC. | $58.98 | 2021-2022 | |
| Medtronic USA, INC. | $55.94 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.79 | 2019-2020 | |
| Sanofi Pasteur INC. | $43.70 | 2020-2022 | |
| Bausch Health US, LLC | $42.49 | 2022 | |
| Abbott Laboratories | $41.50 | 2019 | |
| Daiichi Sankyo INC. | $38.00 | 2019-2022 | |
| Circassia INC. | $31.51 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.13 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $29.68 | 2020 | |
| Radius Health, INC. | $27.62 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.86 | 2022 | |
| Jazz Pharmaceuticals INC. | $24.20 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.59 | 2019 | |
| Scilex Pharmaceuticals INC. | $17.66 | 2019 | |
| Seqirus USA INC | $16.38 | 2022 | |
| Genentech USA, INC. | $16.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Sugarman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.